查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1620662

药物基因体学市场：按产品、技术、适应症和应用分类 - 2025-2030 年全球预测

Pharmacogenomics Market by Product (Consumables, Kits & Reagents, Services), Technology (DNA Sequencing, Electrophoresis, Mass Spectrometry), Indication, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年药物基因体学市场价值为40.6亿美元，预计到2024年将达到44.8亿美元，复合年增长率为10.54%，到2030年将达到82亿美元。

药物基因体学是研究基因如何影响人的药物反应，透过根据个人的基因组成客製化治疗策略，提供更个人化的医学方法。该领域对于推进精准医学、最大限度地减少副作用和提高药物疗效至关重要。药物基因体学学应用涵盖肿瘤学、循环系统、神经病学和感染疾病等多个领域，并被製药、诊断和个人化医疗公司使用。最终用途范围包括希望实施或增强精准医疗能力的医院、研究机构和生物製药公司。

主要市场统计
基准年[2023] 40.6亿美元
预计年份 [2024] 44.8亿美元
预测年份 [2030] 82亿美元
复合年增长率（%） 10.54%

由于对个人化医疗的需求不断增长、不利事件的增加以及基因组定序技术的进步，药物基因体学市场正在不断增长。人工智慧和巨量资料分析的整合带来了巨大的潜在机会，监管机构对基于药物基因体学的药物的核准也越来越多。为了充分利用这些前景，鼓励相关人员专注于研发，与基因组技术公司合作，并对医疗保健专业人员进行药物基因组学测试的好处和应用的教育。

然而，市场面临基因检测成本上升、对基因隐私的伦理担忧以及新兴市场缺乏意识和基础设施等挑战。监管障碍和不良的报销框架也阻碍了市场的成长。

创新和研究的关键领域包括开发更具成本效益的定序技术、增强资料解释软体以及扩大临床试验以提供基于证据的基因药物交互作用的见解。该市场充满活力但又分散，由于支持性政策和成熟的医疗保健系统，新兴经济体具有强劲的成长潜力。对于寻求在药物基因体学领域取得进步的相关人员来说，有效应对现有挑战并利用最尖端科技至关重要。

市场动态：揭示快速发展的药物基因体学市场的关键市场洞察

供需的动态交互作用正在改变药物基因体学市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 慢性病增加和精准医疗需求不断增长
    • 加大医疗基础建设投资
    • 分子诊断相关技术的进步
  • 市场限制因素
    • 与研发相关的高成本
  • 市场机会
    • 个人化医疗和消费者基因检测服务的成长趋势
    • 增加对研发活动的投资以改善药物基因体学
  • 市场挑战
    • 缺乏意识和所需的基础设施

波特五力：驾驭药物基因体学市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解药物基因体学市场的外部影响

外部宏观环境因素在塑造药物基因体学市场的动态表现方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解药物基因体学市场的竞争格局

药物基因体学市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位药物基因体学市场供应商的绩效评估

FPNV定位矩阵是评估药物基因体学市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製药物基因体学市场的成功之路

药物基因体学市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病发生率上升和精准医疗需求
      • 加大医疗基础建设投资
      • 与分子诊断程序相关的技术进步
    • 抑制因素
      • 与研发能力相关的高成本
    • 机会
      • 个人化医疗和消费者基因检测服务的新兴趋势
      • 增加对研发活动的投资以改善药物基因体学
    • 任务
      • 缺乏意识和必要的基础设施
  • 市场区隔分析
    • 技术：聚合酵素链锁反应技术的进步
    • 应用：药物基因体学在各行业的多样化应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章药物基因体学市场：副产品

  • 消耗品
  • 试剂套件和试剂
  • 服务

第七章药物基因体学市场：依技术分类

  • DNA序列分析
  • 电泳
  • 质谱分析
  • 微阵列
  • 聚合酵素链锁反应

第八章药物基因体学市场（按适应症）

  • 神经病学
  • 肿瘤学
  • 疼痛管理

第九章药物基因体学市场：依应用分类

  • 临床诊断实验室
  • 临床研究和药物发现
  • 个人化医疗

第十章美洲药物基因体学市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太药物基因体学市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的药物基因体学市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • SOPHiA GENETICS 宣布扩大与 CHU de Nimes 的业务
    • Diatech Pharmaco Genetics 宣布建立新的合作伙伴关係，以推进肿瘤学的精确测试
    • MyRx 开始提供虚拟药物基因检测咨询
  • 战略分析和建议

公司名单

  • Admera Health
  • Agena Biosciences Inc. by Mesa Laboratories, Inc.
  • BiogeniQ Inc.
  • Castle Biosciences, Inc.
  • CENTOGENE NV
  • Coriell Life Sciences
  • Diatech Pharmacogenetics
  • Dynamic DNA Laboratorie
  • Empire Genomics by Biocare Medical
  • Exceltox Laboratories
  • Genelex Corporation by Invitae
  • Genetworx
  • Genomind
  • GenXys
  • Gravity Diagnostics
  • Illunima Inc.
  • Integra Laboratories
  • Kailos Genetics by healthOme
  • Myriad Genetics Inc.
  • OneOme LLC
  • Personalis Inc.
  • Phamatech Inc. by Caris Life Sciences
  • Quest Diagnostics
  • Thermo Fisher Scientific Inc.
  • ViennaLab Diagnostics GmbH by BioVendor Group
Product Code: MRR-742BD5183871

The Pharmacogenomics Market was valued at USD 4.06 billion in 2023, expected to reach USD 4.48 billion in 2024, and is projected to grow at a CAGR of 10.54%, to USD 8.20 billion by 2030.

Pharmacogenomics is the study of how genes affect a person's response to drugs, offering a more personalized medicine approach by tailoring therapeutic strategies to individuals' genetic make-ups. This field is essential in advancing precision medicine, minimizing adverse drug reactions, and improving drug efficacy. The application of pharmacogenomics spans various areas including oncology, cardiology, neurology, and infectious diseases, and is utilized by pharmaceuticals, diagnostics, and personalized medicine companies. The end-use scope involves hospitals, research institutions, and biopharmaceutical companies seeking to implement or enhance precision medicine capabilities.

KEY MARKET STATISTICS
Base Year [2023] USD 4.06 billion
Estimated Year [2024] USD 4.48 billion
Forecast Year [2030] USD 8.20 billion
CAGR (%) 10.54%

The market for pharmacogenomics is growing due to personalized medicine's increasing necessity, rising adverse drug events, and technological advancements in genomic sequencing. The integration of artificial intelligence and big data analytics presents significant potential opportunities, as does the increasing approval of pharmacogenomic-informed drugs by regulatory bodies. To capitalize on these prospects, stakeholders are recommended to invest in R&D, collaborate with genomic technology firms, and focus on educating healthcare professionals about the benefits and applications of pharmacogenomic testing.

However, the market faces challenges such as high costs of genetic testing, ethical concerns regarding genetic privacy, and a lack of widespread awareness and infrastructure in developing regions. Regulatory hurdles and scarce reimbursement frameworks also impede market growth.

Key areas for innovation and research include developing more cost-effective sequencing technologies, enhancing data interpretation software, and expanding clinical trials to provide evidence-driven insights into gene-drug interactions. The market is dynamic yet fragmented, with significant potential for growth in developed economies due to supportive policies and established healthcare systems. Efficiently addressing the existing challenges and leveraging cutting-edge technologies will be crucial for stakeholders aiming to advance in the pharmacogenomics field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmacogenomics Market

The Pharmacogenomics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of chronic diseases and demand for precision medicine
    • Increasing investments for healthcare infrastructures
    • Technological advancements associated with molecular diagnostics procedure
  • Market Restraints
    • High costs associated with research and development proficiencies
  • Market Opportunities
    • Emerging trend of personalized medicines and direct-to-consumer genetic testing services
    • Rising investment in R&D activities to improve pharmacogenomics
  • Market Challenges
    • Dearth of awareness and required infrastructural facilities

Porter's Five Forces: A Strategic Tool for Navigating the Pharmacogenomics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmacogenomics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmacogenomics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmacogenomics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmacogenomics Market

A detailed market share analysis in the Pharmacogenomics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmacogenomics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmacogenomics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pharmacogenomics Market

A strategic analysis of the Pharmacogenomics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pharmacogenomics Market, highlighting leading vendors and their innovative profiles. These include Admera Health, Agena Biosciences Inc. by Mesa Laboratories, Inc., BiogeniQ Inc., Castle Biosciences, Inc., CENTOGENE N.V., Coriell Life Sciences, Diatech Pharmacogenetics, Dynamic DNA Laboratorie, Empire Genomics by Biocare Medical, Exceltox Laboratories, Genelex Corporation by Invitae, Genetworx, Genomind, GenXys, Gravity Diagnostics, Illunima Inc., Integra Laboratories, Kailos Genetics by healthOme, Myriad Genetics Inc., OneOme LLC, Personalis Inc., Phamatech Inc. by Caris Life Sciences, Quest Diagnostics, Thermo Fisher Scientific Inc., and ViennaLab Diagnostics GmbH by BioVendor Group.

Market Segmentation & Coverage

This research report categorizes the Pharmacogenomics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Consumables, Kits & Reagents, and Services.
  • Based on Technology, market is studied across DNA Sequencing, Electrophoresis, Mass Spectrometry, Microarray, and Polymerase Chain Reaction.
  • Based on Indication, market is studied across Neurology, Oncology, and Pain Management.
  • Based on Application, market is studied across Clinical Diagnostics Labs, Clinical Research & Drug Discovery, and Personalized Medicine.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of chronic diseases and demand for precision medicine
      • 5.1.1.2. Increasing investments for healthcare infrastructures
      • 5.1.1.3. Technological advancements associated with molecular diagnostics procedure
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research and development proficiencies
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging trend of personalized medicines and direct-to-consumer genetic testing services
      • 5.1.3.2. Rising investment in R&D activities to improve pharmacogenomics
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of awareness and required infrastructural facilities
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Advances in Polymerase Chain Reaction technique
    • 5.2.2. Application: Diverse applications of pharmacogenomics across industries
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pharmacogenomics Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Kits & Reagents
  • 6.4. Services

7. Pharmacogenomics Market, by Technology

  • 7.1. Introduction
  • 7.2. DNA Sequencing
  • 7.3. Electrophoresis
  • 7.4. Mass Spectrometry
  • 7.5. Microarray
  • 7.6. Polymerase Chain Reaction

8. Pharmacogenomics Market, by Indication

  • 8.1. Introduction
  • 8.2. Neurology
  • 8.3. Oncology
  • 8.4. Pain Management

9. Pharmacogenomics Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Diagnostics Labs
  • 9.3. Clinical Research & Drug Discovery
  • 9.4. Personalized Medicine

10. Americas Pharmacogenomics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pharmacogenomics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pharmacogenomics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. SOPHiA GENETICS Announces Expansion of Work with CHU de Nimes
    • 13.3.2. Diatech Pharmacogenetics Announces New Collaboration to Advance Precision Testing in Oncology
    • 13.3.3. MyRx launches to provide virtual pharmacogenetic testing consultations
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Admera Health
  • 2. Agena Biosciences Inc. by Mesa Laboratories, Inc.
  • 3. BiogeniQ Inc.
  • 4. Castle Biosciences, Inc.
  • 5. CENTOGENE N.V.
  • 6. Coriell Life Sciences
  • 7. Diatech Pharmacogenetics
  • 8. Dynamic DNA Laboratorie
  • 9. Empire Genomics by Biocare Medical
  • 10. Exceltox Laboratories
  • 11. Genelex Corporation by Invitae
  • 12. Genetworx
  • 13. Genomind
  • 14. GenXys
  • 15. Gravity Diagnostics
  • 16. Illunima Inc.
  • 17. Integra Laboratories
  • 18. Kailos Genetics by healthOme
  • 19. Myriad Genetics Inc.
  • 20. OneOme LLC
  • 21. Personalis Inc.
  • 22. Phamatech Inc. by Caris Life Sciences
  • 23. Quest Diagnostics
  • 24. Thermo Fisher Scientific Inc.
  • 25. ViennaLab Diagnostics GmbH by BioVendor Group

LIST OF FIGURES

  • FIGURE 1. PHARMACOGENOMICS MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACOGENOMICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PHARMACOGENOMICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACOGENOMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACOGENOMICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL RESEARCH & DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. PHARMACOGENOMICS MARKET, FPNV POSITIONING MATRIX, 2023